Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis

IF 2.8 3区医学 Q3 IMMUNOLOGY

Tuberculosis Pub Date : 2024-11-13 DOI:10.1016/j.tube.2024.102577

Hua Zhang , Mengjiao Xue , Xinxin He , Lifang Sun , Qiang He , Yunguang Wang , Juan Jin

{"title":"Altered intestinal microbiota and fecal metabolites in patients with latent and active pulmonary tuberculosis","authors":"Hua Zhang , Mengjiao Xue , Xinxin He , Lifang Sun , Qiang He , Yunguang Wang , Juan Jin","doi":"10.1016/j.tube.2024.102577","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary tuberculosis (PTB) is the main cause of infection-related mortality and the most common infectious disease that develops resistance to antibiotics. Gut microbiota and their associated metabolites are assumed to induce and influence the development of PTB. However, the alterations of gut microbiota and metabolites in TB patients is currently unclear.</div></div><div><h3>Methods</h3><div>Fecal samples were collected from 13 PTB patients, 13 LTBI patients, and 13 healthy controls (HC). 16S rRNA sequencing and metabolomics were used to analyze the changes in the intestinal microbiota and the composition of fecal metabolites in groups.</div></div><div><h3>Results</h3><div>Our findings indicated that the α-diversity of the gut microbiota in patients with PTB and LTBI decreases compared to HC, and at the phylum level, the relative abundance of Firmicutes decreases and the relative abundance of Bacteroides increases. And six genera were notably enriched in PTB patients and four in LTBI patients. Metabolomic analysis showed alterations in metabolite levels, such as short-chain fatty acids and amino acids.</div></div><div><h3>Conclusions</h3><div>we comprehensively explored the changes in the gut microbes and fecal metabolites in patients with PTB and LTBI from the perspective of the gut microbiota, which may provide potential diagnostic biomarkers and therapeutic targets for TB diagnosis and treatment.</div></div>","PeriodicalId":23383,"journal":{"name":"Tuberculosis","volume":"149 ","pages":"Article 102577"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1472979224001033","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Pulmonary tuberculosis (PTB) is the main cause of infection-related mortality and the most common infectious disease that develops resistance to antibiotics. Gut microbiota and their associated metabolites are assumed to induce and influence the development of PTB. However, the alterations of gut microbiota and metabolites in TB patients is currently unclear.

Methods

Fecal samples were collected from 13 PTB patients, 13 LTBI patients, and 13 healthy controls (HC). 16S rRNA sequencing and metabolomics were used to analyze the changes in the intestinal microbiota and the composition of fecal metabolites in groups.

Results

Our findings indicated that the α-diversity of the gut microbiota in patients with PTB and LTBI decreases compared to HC, and at the phylum level, the relative abundance of Firmicutes decreases and the relative abundance of Bacteroides increases. And six genera were notably enriched in PTB patients and four in LTBI patients. Metabolomic analysis showed alterations in metabolite levels, such as short-chain fatty acids and amino acids.

Conclusions

we comprehensively explored the changes in the gut microbes and fecal metabolites in patients with PTB and LTBI from the perspective of the gut microbiota, which may provide potential diagnostic biomarkers and therapeutic targets for TB diagnosis and treatment.

Abstract Image

查看原文本刊更多论文

潜伏期和活动期肺结核患者肠道微生物群和粪便代谢物的变化。

背景：肺结核（PTB）是感染相关死亡的主要原因，也是对抗生素产生抗药性的最常见传染病。肠道微生物群及其相关代谢物被认为会诱发和影响肺结核的发展。然而，目前尚不清楚肺结核患者肠道微生物群和代谢物的变化情况：方法：收集 13 名肺结核患者、13 名长期慢性阻塞性肺病患者和 13 名健康对照者（HC）的粪便样本。采用 16S rRNA 测序和代谢组学分析各组肠道微生物群的变化和粪便代谢物的组成：结果：我们的研究结果表明，与HC相比，PTB和LTBI患者肠道微生物群的α-多样性降低，在门一级，固着菌的相对丰度降低，而乳杆菌的相对丰度升高。有 6 个菌属在 PTB 患者中明显富集，4 个菌属在 LTBI 患者中明显富集。代谢组学分析表明，短链脂肪酸和氨基酸等代谢物水平发生了改变。结论：我们从肠道微生物群的角度全面探讨了肺结核和肺结核患者肠道微生物和粪便代谢物的变化，这可能为肺结核的诊断和治疗提供潜在的诊断生物标志物和治疗靶标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tuberculosis 医学-呼吸系统

CiteScore

4.60

自引率

3.10%

发文量

审稿时长

49 days

期刊介绍： Tuberculosis is a speciality journal focusing on basic experimental research on tuberculosis, notably on bacteriological, immunological and pathogenesis aspects of the disease. The journal publishes original research and reviews on the host response and immunology of tuberculosis and the molecular biology, genetics and physiology of the organism, however discourages submissions with a meta-analytical focus (for example, articles based on searches of published articles in public electronic databases, especially where there is lack of evidence of the personal involvement of authors in the generation of such material). We do not publish Clinical Case-Studies. Areas on which submissions are welcomed include: -Clinical TrialsDiagnostics- Antimicrobial resistance- Immunology- Leprosy- Microbiology, including microbial physiology- Molecular epidemiology- Non-tuberculous Mycobacteria- Pathogenesis- Pathology- Vaccine development. This Journal does not accept case-reports. The resurgence of interest in tuberculosis has accelerated the pace of relevant research and Tuberculosis has grown with it, as the only journal dedicated to experimental biomedical research in tuberculosis.